Skip to main content

ORAGENICS INC

For the period ended Jun 30, 2026. Filed Aug 13, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 13, 2026

OGEN$0.35+1.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 6. Exhibits

ITEM 6.EXHIBITS

The following exhibits are filed herewith, and this list constitutes the exhibit index.

Exhibit NumberExhibit DescriptionFormFile No.Exhibit NumberFiling DateFiled Herewith
3.1Amended and Restated Articles of Incorporation as amended prior to December 29, 2017 (including certificates of designation of Series A, B and C Preferred Stock).8-K001-321883.112/29/17
3.2Articles of Amendment to Amended and Restated Articles of Incorporation dated effective December 29, 2017.8-K001-321883.212/29/17
3.3Articles of Amendment to Amended and Restated Articles of Incorporation effective January 19, 2018.8-K001-321883.101/19/18
3.4Articles of Amendment to Amended and Restated Articles of Incorporation.8-K001-321883.406/26/18
3.5Articles of Amendment to Amended and Restated Articles of Incorporation.8-K001-321883.502/28/22
3.6Articles of Amendment to Amended and Restated Articles of Incorporation8-K001-321883.101/23/23
3.7Amendment to Articles of Incorporation to Increase Common Stock8-K001-321883.112/15/23
3.8Amendment to Amended and Restated Articles of Incorporation8-K001-321883.105/28/25
3.9Certificate of Designation for Series H Preferred Stock8-K001-321883.107/02/25
3.10BylawsSB-2333-1005683.210/16/02
3.11First Amendment to Bylaws8-K001-321883.106/09/10
3.12Second Amendment to Bylaws8-K001-321883.108/24/10
3.13Third Amendment to Bylaws8-K001-321883.902/28/22
4.1Form of Series H Preferred Warrant.8-K001-321884.107/02/25
4.2Warrant Agency Agreement.8-K001-321884.207/02/25
10.1Form of Securities Purchase Agreement8-K001-3218810.107/02/25
10.2Amendment to Sales Agreement, dated January 22, 2026, between Oragenics, Inc. and Dawson James Securities, Inc.8-K001-321881.201/22/26
10.3*Executive Employment Agreement with John Spencer.8-K001-3218810.107/06/26
31.1Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934X
31.2Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934X
32.1Certification of Chief Executive Officer pursuant to Section 1350X
32.2Certification of Chief Financial Officer pursuant to Section 1350X
101.INSInline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCHInline XBRL Taxonomy Extension Schema DocumentX
101.CALInline XBRL Taxonomy Extension Calculation Linkbase DocumentX
101.DEFInline XBRL Taxonomy Extension Definition Linkbase DocumentX
101.LABInline XBRL Taxonomy Extension Label Linkbase DocumentX
101.PREInline XBRL Taxonomy Extension Presentation Linkbase DocumentX
104Cover Page Interactive Data File (formatted in iXBRL, and included in exhibit 101).
  • Executive management contract or compensatory plan or arrangement.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.